Collegium Pharmaceutical’s (COLL) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Friday,Benzinga reports. The brokerage currently has a $60.00 price target on the specialty pharmaceutical company’s stock.

A number of other research analysts also recently issued reports on the company. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Needham & Company LLC cut their target price on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Barclays lowered their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Trading Down 2.2%

COLL opened at $35.49 on Friday. The stock has a market capitalization of $1.13 billion, a P/E ratio of 20.75 and a beta of 0.67. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The firm’s fifty day simple moving average is $43.26 and its 200 day simple moving average is $41.91.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The firm had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same quarter last year, the company posted $1.77 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% on a year-over-year basis. As a group, research analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president directly owned 71,770 shares in the company, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Large investors have recently made changes to their positions in the stock. Group One Trading LLC acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 427 shares during the last quarter. Federated Hermes Inc. lifted its stake in Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 350 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 993 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at about $61,000.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium agreed to acquire AZSTARYS from Corium, adding a differentiated ADHD medicine to its portfolio; company says the asset is expected to generate over $50M in pro‑forma net revenue in H2 2026, offers patent protection into 2037, and the deal is expected to be immediately accretive to adjusted EBITDA. Collegium to Acquire AZSTARYS from Corium Therapeutics (GlobeNewswire)
• Positive Sentiment: Sell‑side support strengthened: HC Wainwright reaffirmed a Buy with a $60 PT and Needham reaffirmed Buy with a $56 PT — both imply substantial upside vs. the recent share price, which can underpin investor confidence. Analyst Coverage (Benzinga)
• Neutral Sentiment: Conference call and management discussion transcripts are available for investors seeking details on deal economics and integration plans. Acquisition Discussion Transcript (Seeking Alpha)
• Neutral Sentiment: FDA news elsewhere in the pharma sector: PharmExec reports approval of Wegovy HD (Novo Nordisk) — relevant for sector context but not directly tied to Collegium’s ADHD/pain-focused franchise. FDA Approves Wegovy HD (PharmExec)
• Neutral Sentiment: Public press coverage shows deal price described with varying figures (reports cite up to $785M and also $650M headlines) — read releases for definitive terms. Collegium to buy AZSTARYS for up to $785M (MSN)
• Negative Sentiment: The acquisition costs and financing raise near‑term financial risk: the deal is being funded from cash on hand plus a previously announced $300M delayed‑draw term loan, which increases leverage for a company that already shows a relatively high debt/equity ratio; investors may worry about cash burn, integration execution and balance‑sheet pressure. Deal Coverage (FiercePharma)
• Negative Sentiment: Recent quarterly results (Feb. 26) showed a slight revenue and EPS miss vs. consensus, which combined with the large acquisition outlay can pressure near‑term sentiment as investors await proof the deal accelerates growth. Earnings Summary (Benzinga)
• Neutral Sentiment: Reported short‑interest data appears anomalous (shows zero shares), so it does not provide a meaningful read into market positioning at this time.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.